Neuromed's long-acting opioid Exalgo heads for US panel review
This article was originally published in Scrip
Executive Summary
The US FDA's anaesthetic and life support drugs advisory panel will review Neuromed Pharmaceuticals' extended-release opioid Exalgo (hydromorphone HCl) on September 23rd. The proposed indication is treatment of moderate to severe pain in opioid-tolerant patients.